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Abstract 
 
Introduction and Aims: Police Services in a number of Australian states have indicated random 
roadside drug testing will be implemented to target drug driving. This paper outlines research 
conducted to provide an estimate of the prevalence of drug driving in a sample of Queensland 
drivers.  
Design and Methods: Oral fluid samples were collected from 781 drivers who volunteered to 
participate at Random Breath Testing (RBT) sites in a large Queensland regional area. Illicit 
substances tested for included cannabis (delta 9 tetrahydrocannibinol [THC]), amphetamine type 
substances, heroin and cocaine. Drivers also completed a self-report questionnaire regarding their 
drug-related driving behaviour. Samples that were drug-positive at initial screening were sent to a 
government laboratory for confirmation.  
Results: Oral fluid samples from 27 participants (3.5%) were confirmed positive for at least one 
illicit substance. The most common drugs detected in oral fluid were cannabis (delta 9 THC) (n = 
13) followed by amphetamine type substances (n = 11). A key finding was that cannabis was also 
confirmed as the most common self-reported drug combined with driving and that individuals who 
tested positive to any drug through oral fluid analysis were also more likely to report the highest 
frequency of drug driving.  Furthermore, a comparison between drug vs drink driving detection 
rates for the study period revealed a higher detection rate for drug driving (3.5%) vs drink driving 
(0.8%).   
Discussion and Conclusion: This research provides evidence that drug driving is relatively 
prevalent on Queensland Roads.  The paper will further outline the study findings and present 
possible directions for future drug driving research.   
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Introduction 
 
The role of alcohol in road crashes is well documented, and through enforcement practices such as 
Random Breath Testing, estimations have been obtained regarding the proportion of the general 
driving population (who are not involved in crashes) that continue to drive after consuming alcohol. 
In contrast, the prevalence of drug involvement in crashes, and the proportion of the general driving 
population (who are not involved in crashes) that are driving after consuming drugs remain limited. 
It has been argued that one of the primary reasons for this discrepancy is the difficulty associated 
with identifying and measuring drug use by drivers, as the process is considerably more complex 
than alcohol analysis [1].  In addition, a variety of drugs can influence driving performance, and 
each drug type requires a specific test [1].   
 
At present, the majority of previous research that has attempted to examine drug driving for 
different driver groups has focused predominately on samples of body fluids from individuals 
involved in crashes [2-5].  Research indicates that between 8.8 and 26.7 percent of drivers fatally 
injured in crashes have drugs detected in their body fluid [2-5].  In addition, drugs are detected in 
2.7 to 41.3 percent of non-fatally injured drivers in traffic crashes [6,7]. 
 
In contrast, considerably less data is available for non-crash involved drivers, and the majority of 
this data tends to be self-reported [1, 8- 15].  A number of Australian and Canadian studies have 
implemented self-report drug driving surveys within a variety of different samples, including: illicit 
drug users [12]; truck drivers [13]; people who have attended “rave” dance parties [15]; and general 
drivers [1,8, 9, 10, 11]. Self-reported frequency of drug driving for illicit drug users varies between 
two and 90 percent of respondents, and is largely dependent on whether participants were 
responding generally or with reference to a specific drug. The most common drugs are usually 
cannabis, heroin and amphetamines, however a limitation of this research is that the majority of 
previous studies have only sampled cannabis users. 
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Alternatively, studies involving body fluid sample analysis predominantly involve samples of 
drivers suspected of driving under the influence of alcohol and/or drugs, while very few published 
studies have analysed body fluid samples from a sample of drivers. One of the few studies in this 
area reported that among a random sample of non-crash involved drivers in Britain, 4.7 percent of 
drivers provided drug-positive samples [16]. However, to date there is no such data available for 
Australian drivers. While it is recognised that the Victorian Police Service trial of random roadside 
drug testing is currently underway, at the time of publication, scientific data was not publicly 
available. 
   
Roadside detection using oral fluid samples 
It has been argued that advances in testing for drugs in oral fluid are “fundamental to the 
introduction of on-site, and in particular, roadside testing”, with the time taken to collect a sample 
appropriate for a roadside test [17].  The use of oral fluid in drug testing is particularly 
advantageous for roadside use, as sample collection is relatively simple and non-invasive [17,18]. 
From an enforcement perspective, collection of oral fluid samples can be supervised without 
causing embarrassment to the participant, making the sampling technique resistant to tampering or 
adulteration, while preserving the dignity of the participant [17-19]. Oral fluid analysis is useful in 
detecting very recent drug use, as this technique detects the presence of the free, unbound parent 
drug(s) [17-19].  
Current project objectives 
In summary, a further review of the drug driving literature concluded that the drugs detected in 
impaired drivers usually reflect the general drug use patterns of the community in which the studies 
were conducted [20].  Therefore the drugs that will pose the greatest risk to traffic safety in a given 
community, and any countermeasures implemented to reduce this risk, must be determined by the 
drug use patterns observed in that community. However, no such data is available for Queensland 
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drivers. For example, in an issues paper on drug driving in Queensland, the Parliamentary 
Travelsafe Committee identified the need for research to “establish the patterns of drug use by 
Queensland drivers” [21, 1998, p. 10]. 
 
As a result, the major objectives of this study were to: 
• Measure the prevalence of drug driving among a sample of Queensland drivers,  
• Investigate the self-reported frequency of general motorists’ involvement in drug driving 
behaviour; and 
• Independently assess the reliability of current mobile drug screening technology.  
Method  
Participants, Materials and Procedure 
Drivers stopped at Random Breath Testing operations across a large regional area of Queensland 
were approached and asked by operational police to participate in the drug driving research, which 
was positioned on average 50 metres further down the road. Participation was voluntary and 
involved completing a self-report questionnaire regarding recent illicit drug use and drug driving in 
the previous 12 months, and providing a sample of oral fluid that could later be screened for the 
presence of drugs. The procedure took approximately 10-20 minutes to complete and drivers 
received a one-off payment of $20 cash to reimburse them for their time.  Data was collected over a 
two month period, on ten separate occasions, usually between the hours of 5pm and 1am1.   
 
A 12 item self-report questionnaire was designed to assess a variety of demographic data (e.g., 
gender, age, years driving) as well as self-reported drug use and the frequency of drug driving 
behaviour.  Participants responded to questions that investigated the most recent use of marijuana / 
cannabis (within four hours, within the last 24 hours, within the last week, within the last month, 
                                                 
1 Workplace health and safety requirements resulted in the current roadside project only being implemented with 
the presence of the Queensland Police Service.  RBT operations were deemed to be the most compatible 
roadside activity and thus drug testing procedures corresponded within traditional RBT operational hours e.g., 
5pm – 1am.   
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within the last year, more than a year ago, have never used). This question was repeated for meth / 
amphetamine type substances (such as speed, oil, base, crystal), heroin and cocaine. Participants 
were also required to indicate how often in the previous 12 months they had operated a motor 
vehicle (including a motorcycle) within four hours of using marijuana / cannabis (every day, more 
than once a week, about once a week, 11 – 20 times, 3 – 10 times, once or twice, never). Once 
again, this question was repeated for meth / amphetamine type substances (such as speed, oil, base, 
crystal), heroin and cocaine. The majority of data was descriptive and/or categorical, and recorded 
as percentage frequencies, and thus, chi-square tests were performed where appropriate.   
 
In addition, oral fluid samples were collected, stored and screened off-site at a later date using the 
Cozart® RapiScan oral fluid drug test device. Participants provided a sample of oral fluid that was 
collected from inside their mouth via a pad held either under their tongue or beside the inside of 
their cheek.  The five-panel cannabis and single-panel methamphetamine / MDMA test cartridges 
were used (i.e. each sample was screened twice). Each Cozart® RapiScan kit consisted of a 
collector, transport tube containing buffer solution, separator filter tube, pipette and test cartridge. 
The five-panel cannabis cartridge detected the presence of benzodiazepines, amphetamine type 
substances, cannabis (THC), cocaine and opiates, while the single-panel methamphetamine / 
MDMA cartridge detected the presence of methamphetamine and MDMA (ecstasy). There was no 
subjectivity in the interpretation of results as the Cozart® RapiScan testing instrument displayed 
and printed results. 
 
All drug-positive samples and a random group of negative samples were sent to a government 
laboratory for confirmatory analysis, specific drug type analysis, and to quantify the level of the 
drug(s) in the sample. Samples were analysed using Gas Chromatography – Mass Spectrometry 
(GC-MS) (for cannabinoids and amphetamine type substances) and Liquid Chromatograph tandem 
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Mass Spectrometer (LC/MS/MS) (for opiates and cocaine) techniques. Quantities of 0.2 to 0.4 
millilitres of sample were used for each analysis.  
RESULTS 
Sample and Response Rate 
A total of 781 motorists participated in the study.  Due to resourcing constraints and the referral 
process from the Police RBT site, it was not possible to obtain an accurate measurement of the 
response rate over the entire data collection period2. However, on one occasion the response rate 
was assessed across two sites during a shift where an additional researcher counted the number of 
drivers approached to participate and noted their response. Drivers of 63 cars from a total of 85 
participated in the project, resulting in a response rate of 74.12 percent. In addition, over the entire 
study, six potential participants approached the research site, but declined to participate after being 
informed about the research procedure.    
 
More than half the participants were male (n = 475, 61.6%), aged between 16 and 66 years (mean 
age = 26.35 years, SD = 10.46). On average, participants had been driving for 9.04 years (SD = 
10.03). Most reported driving daily (n = 581, 75.7%) or three to five times per week (n = 156, 
20.3%).  
Prevalence of Positive Drug Tests 
Laboratory confirmation revealed that oral fluid samples from 27 drivers (3.5% of the total sample) 
contained at least one illicit substance.  However, a comparison with the corresponding drink 
driving detection rates for the associated RBT cite revealed a 0.8% apprehension rate, as 27 positive 
results were identified from 3,230 random breath tests conducted3.  Table 1 outlines the results by 
drug group detected and gender of the driver. As depicted in Table 1, the most common drug 
detected was delta 9 THC only, followed by amphetamine type substances only, while samples 
                                                 
2 The procedure usually consisted of RBT operational police officers informing motorists (who had given a 
breath sample) that they had the opportunity to participate in an anonymous research drug driving project being 
conducted approximately 100 metres down the road.   
3 Relatively few individuals charged with drink driving participated in the drug driving research, and thus the 
drug and drinking drivers consisted of separate samples.   
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from three drivers were consistent with polydrug use, as they contained both delta 9 THC and 
amphetamine type substances. When separated by gender (where gender was known), the 
prevalence of drug driving was higher among males than females. All polydrug users were male. 
 
More specifically, of the 14 samples that were confirmed positive for the presence of amphetamine 
type substances: two samples contained methylamphetamine only, four samples contained MDMA 
only, one sample contained methylamphetamine and MDMA, four samples contained 
methylamphetamine and amphetamine, and three samples contained methylamphetamine, MDMA 
and amphetamine. All of the 16 samples that were confirmed positive for the presence of cannabis 
(THC) contained delta 9 THC, which is the active component of cannabis associated with a drug-
induced state.  Furthermore, the presence of delta 9 THC in oral fluid indicates very recent use of 
cannabis, as it is metabolised out of the body within hours.  
 
Compared with the total participant pool, the 27 drivers who provided samples that were confirmed 
positive for at least one illicit substance were more likely to be male (n = 23, 85.2%), and aged 
between 17 and 30 (mean = 22.48 years, SD = 3.92), and had less driving experience than the 
sample average (mean = 5.73 years, SD = 4.38). Frequency of driving was similar, as most reported 
driving daily (n = 22, 84.6%) or three to five times per week (n = 3, 11.5%). 
 
INSERT TABLE 1 HERE 
 
Reliability of current mobile screening technology 
Finally, an additional analysis was undertaken to confirm the accuracy and sensitivity of the drug 
testing apparatus utilised in the current study. Examination of the data revealed the accuracy of the 
Cozart® RapiScan device was 90.6 percent for positive samples (n = 30) and 100 percent for 
negative samples (n = 37). For example, three samples that were positive for amphetamine type 
substances at initial screening were not confirmed by the laboratory. All of the samples that were 
negative for all drugs at initial screening were subsequently confirmed as negative at the laboratory, 
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or small concentrations of drugs were identified that were deemed below the detection cut-off of the 
Cozart® RapiScan device. 
 
Self-reported Prevalence of Drug Driving 
In addition to the analysis of body fluids, an investigation was also undertaken to examine 
participants’ self-reported drug use and drug driving behaviours.  Firstly for drug use, the most 
commonly consumed drug was cannabis, with 26.6% reporting the use of the substance within the 
last year, and 10% of this group reporting usage in the last week.  In contrast, only 8.1% reported 
amphetamine use in the last year, with 1.9% using the substance in the last week.  Finally, 2.3% 
reported using cocaine and 0.4% of the sample reported using heroin during the last year. Chi-
square analysis revealed males were more likely to report regular cannabis use than females X2 (6, 
N = 781, = 21.71, p = .001), while small cell sizes precluded analysis of the other substances.      
 
For drug driving, similar to the above findings, the most common substance combined with driving 
was cannabis (see Table 2).  Specifically, 4.7% reported using cannabis before driving at least once 
a week, while less than 1.0% reported the use of amphetamines, cocaine or heroin before driving.  
Finally, examination of the self-reported drug use for the 27 individuals who tested positive to the 
presence of drugs revealed that drug driving was most common among these individuals.  For 
example, 21 (84%) reported driving within four hours of using at least one of the drugs outlined on 
the questionnaire. This proportion is more than four times the proportion of the total sample of 782 
drivers that reported drug driving (134 drivers, 18%). In addition, fourteen (51.9%) of the drivers 
who provided samples that were confirmed positive for at least one illicit substance reported drug 
driving frequently (that is, once a week or more). This is more than 10 times the proportion of the 
total sample that reported frequently drug driving (39 drivers, 5%).  
 
INSERT TABLE 2 HERE 
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DISCUSSION 
 
This paper aimed to report on an investigation into the incidence of drug driving in a Queensland 
region.  Specifically, the study focused on measuring the self-reported prevalence of drug driving 
in the community, the major drug types that may be used when driving, and the reliability of 
current mobile drug screening technology.   
 
Prevalence of Positive Drug Tests 
The first major finding of the study was that the examination of oral fluid samples revealed that 
3.5% (n = 27) of the sample provided a positive illicit drug reading.  The finding is consistent with 
one of the few studies in this area that reported approximately 4.7% of non-crash involved drivers 
provide positive drug samples [16].  However, a comparison with the corresponding drink driving 
detection rates for the associated RBT cite revealed a greater percentage of identified drug drivers 
than drink drivers.  Whilst only preliminary, the results suggest that a greater proportion of drivers 
may be at risk of driving under the influence of drugs, rather than alcohol, in the early hours of the 
morning.  Furthermore, considering that previous research has indicated that perceptions of 
apprehension certainty are a key element in deterring both drink drivers [22] and drug drivers [23] 
from engaging in such offending behaviours, drug testing through saliva techniques has the 
potential to become a viable method to increase perceptions of apprehension certainty and thus 
reduce driving under the influence of illicit drugs.  One of the next steps may include examining 
motorists’ current perceptions regarding the likelihood of being detected for drug driving, and their 
corresponding beliefs about the effectiveness, and impact, of saliva testing on offending rates.   
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In the current study, these drivers were predominantly male and were under the age of 30. Two 
types of drugs were detected: cannabis (delta 9 THC); and amphetamine type substances. Also more 
than half of the samples confirmed positive for the presence of amphetamine type substances 
contained more than one substance. One possible explanation for the detection of more than one 
amphetamine type substance in a number of samples is more likely the result of the manufacture of 
the drug used (such as ecstasy) as opposed to use of multiple drugs.  In addition, it is noteworthy 
that amphetamine is a metabolite of methamphetamine and hence could be detected when only the 
latter is taken.  Further research appears required to examine what percentage of motorists engage 
in poly drug use before driving.   
 
Reliability of current mobile screening technology 
The Cozart® RapiScan device is an on-site test designed to screen samples at the point of 
collection.  An analysis undertaken to examine the reliability of the drug testing apparatus utilised 
in the current study revealed a relatively high level of accuracy with 90.6% for positive samples (n 
= 30) and 100% for negative samples (n = 37). The slight variance in positive samples may be due 
to a number of factors.  Firstly, it is noted that the samples were frozen (i.e., packed on ice for 
preservation) after collection, and were therefore thawed before initial screening.  Secondly, there 
was also some delay between the initial screening and laboratory confirmation i.e., 2 – 6 weeks. As 
a result, it is anticipated that the three false positive results in this study were more likely the result 
of the procedures implemented in this project rather than limitations of the technology.  Despite the 
data collection difficulties, initial results of the mobile screening technology appear to suggest the 
device may be relatively robust and has the potential to be utilised as a drug screening method.  
However, further research is required to determine the sensitivity of the technology with different 
drug groups, as preliminary evidence suggests the device is able to detect amphetamine type 
substances more easily than THC due to lower minimum levels of detection for amphetamine type 
substances and the amount of time the drugs remain in oral fluid.  
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Self-reported Prevalence of Drug Driving 
Examination of the self-reported data revealed that cannabis was the most frequently consumed 
illicit substance, and not surprisingly, was also the most frequent drug to be used when driving.  
The findings support previous research that has indicated cannabis to be the most prevalent drug 
associated with driving [3-5].  In addition, individuals who tested positive to the drug testing 
process also reported the highest rate of drug driving.  As a result, the findings also provide 
preliminary evidence that positive drug testing outcomes highlight individuals at risk of regularly 
engaging in drug driving activity, and at some level, provide support for the reliability of the self-
report data.   
 
Limitations  
However, some methodological limitations associated with the program of research should be borne 
in mind when interpreting the findings.  The results of the study may not be generalisable, as a 
regional sample from only one area of Queensland was utilised in the research project.  It is 
possible that drug use (and therefore, drug driving) trends may vary by area, due to differences in 
the supply, demand, cost and potency of drugs. It is therefore recommended that this research be 
replicated on a larger scale to sample drivers from across Queensland, with urban, regional and 
rural samples. Such information will assist in the development and implementation of effective 
countermeasures to combat drug driving. Further, although a wide age range was observed, the 
sample was heavily skewed towards younger age groups (the median age was 22 years). It would 
have been ideal to have sampled a group of drivers more representative of all Queensland drivers, 
however due to the voluntary nature of the study, this did not occur. It is possible, however, that the 
sample of this study is representative of drivers at night on weekends, which is when data collection 
was conducted.  However, given that data was only collected between the hours of 5pm and 1am, it 
is possible that drug driving rates may increase or decrease further into the early hours of the 
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morning, as well as during the day.  Furthermore, the possibility of volunteer bias remains, as 
approximately one in four drivers declined to participate, and although the Queensland Police 
Service were not directly involved in the research project, it is possible that operational officers 
presence at the research cite deterred some individuals from participating (especially those under 
the influence of drugs).  Questions also remain about the accurateness of saliva testing for illicit 
drugs, as environmental contamination may negatively affect the accuracy of oral testing e.g., 
presence in a room where cannabis is being smoked.  Finally, a further limitation of this study was 
the delay between sample collection, screening and laboratory confirmation, which may have 
influenced the reliability of the collected samples.  Unfortunately, it was beyond the scope of this 
study to screen the samples at the roadside due to resourcing constraints. While only three samples 
were not confirmed by the laboratory (which would suggest that this delay had a minimal effect on 
results), the true impact of this procedure is unknown and future research should attempt to 
minimise the delay between sample collection, screening and laboratory confirmation.    
 
Taken together, this was an innovative project as it was the first Australian study to provide 
valuable information regarding the drug use and drug driving behaviour of a sample of drivers that, 
to date, has been lacking in the drug driving literature. The interception of participants while 
engaged in the driving task was also unique. Perhaps the most surprising finding of this study was 
that people who had used drugs recently still volunteered to participate in the research. When 
considered in conjunction with the high response rate of the study, this suggests that it is possible to 
obtain a valid estimate of the incidence of drug driving in the community using a volunteer sample 
when the anonymity of participants is assured.  Also, the collection of two types of data (i.e. self-
report and oral fluid samples) permitted the researchers to objectively assess the accuracy of the 
self-report data provided by participants. Relying on self-report data alone can be problematic when 
researching illegal or sensitive behaviours, particularly in close proximity to the Police (as was the 
case in this study), as participants may be motivated to conceal their behaviour. Despite this, 
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matching self-report data to results of oral fluid sample analysis in this study revealed that 
participants’ self-reported responses were relatively reliable.  In summary, further examination into 
drug use and drug driving can only prove beneficial to policy development, and the design of 
effective countermeasures and enforcement practices aimed at reducing the impact of this growing 
road safety problem.   
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Tables 
 
Table 1. Number and Proportion of Participants by Drug Group  
 
 Total
4 
N = 781 
Males 
N = 475 
Females 
N = 296 
Cannabis (THC) only  13 (1.7%)  12 (2.5%)  1 (0.3%) 
Amphetamine Type Substances (ATS) only  11 (1.4%)  8 (1.7%)  3 (1.0%) 
Polydrug Use (ATS & THC)  3 (0.4%)  3 (0.6%)  0 
Total Illicit Substances  27 (3.5%)  23 (4.8%)  4 (1.4%) 
 
 
Table 2. Drug Driving Behaviour 
Cannabis Amphetamine Cocaine Heroin Drug Type n % n % n % n % 
Drug Driving 
 Every day 
 More than once week 
 About once a week 
 11 - 20 times 
 3 - 10 times 
 Once or twice 
 Never 
 
 14 
 13 
 10 
 9 
 15 
 63 
 632 
 
(1.8) 
(1.6) 
(1.3) 
(1.1) 
(1.9) 
(8.3) 
(84) 
 
 
 1 
 2 
 3 
 8 
 5 
 17 
 722 
 
(0.1) 
(0.3) 
(0.4) 
(1.0) 
(0.6) 
(2.1) 
(95.5)
 
 1 
 2 
 0 
 0 
 0 
 0 
 755 
 
(0.1) 
(0.3) 
(0.0) 
(0.0) 
(0.0) 
(0.0) 
(99.6) 
 
 1 
 0 
 0 
 0 
 0 
 2 
 755 
 
(0.1) 
(0.0) 
(0.0) 
(0.0) 
(0.0) 
(0.3) 
(99.6)
 
 
                                                 
4 10 respondents did not provide their gender. 
